Floatz logo

Epirubicin

Recurrent

Sunnybrook Health Sciences CentrePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

1 Active assets in the Recurrent cohort.

Asset / SponsorPhaseRating
Azacitidine
The Second Hospital of Shandong University
Phase 1/2CC
FILGRASTIM
The Second Hospital of Shandong University
Phase 1/2CC
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 1/2CC

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →